Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.60 |
| ▸ | F3 | P13726 | 1/20 | 0.60 |
| ▸ | PYGL | P06737 | 5/20 | 0.60 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | NHERF1 | O14745 | 4/20 | 0.56 |
| ▸ | BCAT1 | P54687 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24740532 | 0.88 | ALOX15 (0.71) | F7F3PYGLHRH4HRH3 | |
| SCHEMBL17149709 | 0.84 | NHERF1 (0.57) | F7F3PYGLHRH4HRH3 | |
| SCHEMBL14845703 | 0.84 | PIN1 (0.62) | HRH4RXFP1ALOX15NPC1RAB9A | |
| SCHEMBL12101200 | 0.83 | ALOX15 (0.77) | F7F3PYGLHRH4HRH3 | |
| SCHEMBL13334344 | 0.82 | TP53 (0.47) | PYGLHRH4MEN1KMT2ARXFP1 | |
| SCHEMBL19901352 | 0.82 | HRH4 (0.51) | PYGLHRH4HRH3KMT2ARXFP1 | |
| SCHEMBL12669766 | 0.80 | KDM4E (0.64) | NPC1RAB9AFLT3 | |
| SCHEMBL4933623 | 0.80 | F7 (0.66) | F7F3PYGLHRH4HRH3 | |
| SCHEMBL27464367 | 0.80 | F7 (0.66) | F7F3PYGLHRH4HRH3 | |
| SCHEMBL24198791 | 0.80 | F7 (0.66) | F7F3PYGLHRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | F7 1532/4885F3 553/4885PYGL 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.